venBio Partners
venBio is a life sciences investment firm that partners with industry leaders to build game-changing medicines and technologies.
Business Model:
Revenue: $5.7M
Employees: 2-10
Rankings
Industries / Tags:
Detailed venBio Partners Information
Geographic Data
Address: 1700 Owens St
City: San Francisco
State: CA
Zip: 94158
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$2B
Social
Facebook
Linkedin
Crunchbase
Metrics
9,736,746Website Global Rank
107Website Monthly Traffic
Twitter Followers
Description
venBio invests in promising companies at various stages: from early to late stage, and from academic startups to spinouts. We tend to lead most of our investments, and we enjoy building syndicates and teams. We are mindful of potential acquisition partners from the outset, and we ensure that our companies are best positioned to meet their requirements. This includes IP, CMC, and the details of clinical trials, including indication, trial design, endpoints, powering, and regulatory considerations. Our team’s expertise and involvement helps companies make a bigger impact, and this leads to impactful and lasting relationships with the leaders that we work with.
Contact Phone:
+14158000800
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 10/2019 | INBRACE | Series C | 45M |
| 7/2015 | Outlook Therapeutics | Venture Round | 31M |
| 10/2021 | HistoWiz | Series A | 32.3M |
| 2/2015 | Cidara Therapeutics | Series B | 42M |
| 3/2017 | ALX Oncology | Convertible Note | 25M |
| 9/2019 | Pharvaris | Series B | 66M |
| 8/2021 | Neurogastrx | Series B | 60M |
| 1/2021 | FogPharma | Series C | 107M |
| 6/2018 | Akero Therapeutics | Series A | 65M |
| 4/2014 | Heart Metabolics | Series A | 20M |
| 12/2013 | Stem Cell Therapeutics | Post-IPO Equity | 0 |
| 11/2020 | Pharvaris | Series C | 80M |
| 2/2014 | Aurinia Pharmaceuticals | Post-IPO Equity | 52M |
| 6/2018 | Precision BioSciences | Series B | 0 |
| 1/2022 | ImmPACT Bio | Series B | 0 |
| 1/2018 | Neurogastrx | Series A | 45M |
| 2/2016 | Apellis Pharmaceuticals | Series D | 47M |
| 9/2020 | Attralus | Series A | 25M |
| 11/2020 | Elevation Oncology | Series B | 65M |
| 12/2016 | Impel NeuroPharma | Series C | 36M |
| 2/2020 | ALX Oncology | Series C | 105M |
| 12/2018 | Akero Therapeutics | Series B | 70M |
| 6/2020 | Artiva Biotherapeutics | Series A | 0 |
| 11/2020 | Stargazer Pharmaceuticals | Series A | 0 |
| 10/2013 | Seragon Pharmaceuticals | Series A | 30M |
| 3/2015 | ALX Oncology | Series A | 36M |
| 10/2020 | RayzeBio | Series A | 45M |
| 12/2018 | Impel NeuroPharma | Series D | 67.5M |
| 12/2020 | Tallac Therapeutics | Series A | 62M |
| 9/2015 | Outlook Therapeutics | Venture Round | - |
| 1/2022 | Ceptur Therapeutics | Series A | 0 |
| 9/2021 | Attralus | Series B | 116M |
| 3/2012 | Cytos | Post-IPO Equity | 40M |
| 6/2020 | Checkmate Pharmaceuticals | Series C | 85M |
| 9/2014 | Adaptimmune | Series A | 0 |
| 10/2017 | Harmony Biosciences | Venture Round | 0 |
| 7/2017 | VYNE Therapeutics | Series C | 50.5M |
| 12/2022 | Entact Bio | Series A | 81M |
| 1/2020 | NorthSea Therapeutics | Series B | 40M |
| 12/2012 | Solstice Biologics | Private Equity Round | 7.5M |
| 8/2015 | Checkmate Pharmaceuticals | Series A | 20M |
| 1/2013 | Labrys Biologics | Series A | 31M |
| 9/2021 | Ventyx Biosciences | Series B | 0 |
| 8/2014 | Bellicum Pharmaceuticals | Series C | 55M |
| 6/2018 | Metacrine | Series C | 65M |
| 4/2019 | Arrakis Therapeutics | Series B | 75M |
| 9/2022 | ACELYRIN | Series C | 0 |
| 10/2019 | Aeovian Pharmaceuticals | Series A | 0 |
| 10/2012 | Aragon Pharmaceuticals, Inc. | Series D | 50M |
| 12/2018 | Checkmate Pharmaceuticals | Series C | 22M |
| 8/2015 | Metacrine | Series A | 36M |
| 11/2021 | ACELYRIN | Series B | 0 |
| 12/2017 | Metacrine | Series B | 22M |
| 2/2021 | Artiva Biotherapeutics | Series B | 120M |
| 12/2020 | RayzeBio | Series B | 105M |
| 6/2020 | NFlection Therapeutics | Series A | 20M |
| 8/2017 | Apellis Pharmaceuticals | Series E | 0 |
| 6/2017 | Checkmate Pharmaceuticals | Series B | 27M |
| 12/2021 | NorthSea Therapeutics | Series C | 0 |
| 3/2021 | Ventyx Biosciences | Series A | 0 |
| 6/2021 | RayzeBio | Series C | 108M |
| 10/2018 | Turning Point Therapeutics | Equity | 80M |
| 10/2021 | CinCor Pharma | Series B | 0 |
| 11/2022 | FogPharma | Series D | 0 |
| 1/2013 | Solstice Biologics | Series A | 18M |
| 9/2021 | INBRACE | Series D | 0 |
| 5/2015 | Precision BioSciences | Series A | 0 |
| 11/2021 | Ablaze Pharmaceuticals | Series A | 0 |
| 1/2022 | ImmPACT Bio | Series B | 0 |
| 1/2022 | Ceptur Therapeutics | Series A | 0 |
| 12/2021 | NorthSea Therapeutics | Series C | 0 |
| 11/2021 | Ablaze Pharmaceuticals | Series A | 0 |
| 11/2021 | ACELYRIN | Series B | 0 |
| 10/2021 | HistoWiz | Series A | 0 |
| 10/2021 | CinCor Pharma | Series B | 0 |
| 9/2021 | Ventyx Biosciences | Series B | 0 |
| 9/2021 | INBRACE | Series D | 0 |
| 9/2021 | Attralus | Series B | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
